|Day Low/High||50.08 / 51.55|
|52 Wk Low/High||36.28 / 80.66|
With a $31 billion debt load, the drugmaker has to show it has the firepower needed to fend off creditors.
The company could divest non-core assets after Starboard Value revealed a 4.6% stake.
The pharmaceutical company is reportedly up for sale after being dogged by Starboard Value for months, and could go for up to $41 million.
Here's a technical look at how to trade some of the most active stocks on the market right now.
Stocks rise Monday after Federal Reserve Gov. Lael Brainard urges 'prudence' in raising rates.
Stocks climbed, though worries over how soon the Federal Reserve might hike interest rates kept markets wary.
The activist fund says Perrigo's promises over the past year have been "woefully unfulfilled."
Stocks pare gains on Monday as worries over how soon the Federal Reserve might hike interest rates keeps markets wary.
Perrigo is the second drug company that the activist has targeted in recent months after it rejected an unsolicited bid.
Falling crude oil prices continued to weigh on markets Monday.
Stock futures moved sharply lower on Monday morning, extending Friday's selloff, as worries continued over how soon the Federal Reserve might hike interest rates.
Starboard Value disclosed a 4.6% stake in Perrigo (PRGO) stock, and now wants the company to explore a sale of its prescription pharmaceuticals business.
David Einhorn's Greenlight Capital initiated positions in these stocks in the second quarter. Here's a technical look at how to trade them now.
David Einhorn is a man of many talents, including playing poker -- and watching where he stacks his chips investment-wise is a worthwhile endeavor, too.
Deutsche Bank lowered its price target to $105 on Perrigo (PRGO) stock this morning.
U.S. stocks edged back from records highs set last week as resurfacing supply worries took a chunk out of crude prices.
Ralph Lauren shares surge on earnings beat amid lethargic market action.
Perrigo (PRGO) posted weak earnings for the 2016 second quarter and cut its full-year forecast, which Jim Cramer found 'disturbing.'
Despite cutting its full year guidance, the company continues to have a lot of potential upside.
Perrigo might have been in more of a decline than the market realized when it turned down Mylan's $26 billion offer for the company last year, says Jim Cramer.
I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.
The stock's tumbling to near a 52-week low, but charts suggest caution.
Perrigo (PRGO) reported earnings for the 2016 second quarter, falling short of estimates and cutting guidance for the year.
Perrigo (PRGO) is expected to report second-quarter earnings and revenue that fell from a year ago before tomorrow's market open.
Much to the relief of Bill Ackman and other investors, the Joe Papa-led company also reaffirmed its 2016 guidance on Tuesday.
The stock is up on earnings but there could be violations in agreements with creditors.
Analysts say Tuesday's earnings beat could spell trouble in terms of coping with its $31 billion worth of debt.
Cramer says he'll be watching Allergan, Tyson and Macy's earnings, among many others. Also, he explains why having money in the stock market is the best path to long-term rewards.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.